TR200100234T2 - Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması. - Google Patents
Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması.Info
- Publication number
- TR200100234T2 TR200100234T2 TR2001/00234T TR200100234T TR200100234T2 TR 200100234 T2 TR200100234 T2 TR 200100234T2 TR 2001/00234 T TR2001/00234 T TR 2001/00234T TR 200100234 T TR200100234 T TR 200100234T TR 200100234 T2 TR200100234 T2 TR 200100234T2
- Authority
- TR
- Turkey
- Prior art keywords
- sulfamate
- biogenic estrogen
- substitution therapy
- hormone substitution
- sulfamates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Abstract
Biyojen estrojensülfamatlarin hormon substitusyon terapisinde (HRT) oral, kesintili uygulanmasinda kullanimi açiklanmaktadir. Kesintili verme 2-40 günlük araliklarla gerçeklestirilmektedir. Ek olarak gestajenlerin de, tercihen sürekli biçimde bir implantat veya intraoterin bir serbest birakma sistemi seklinde (IUD) uygulanmasi öngörülmüstür. Biyojen estrojensülfamat olarak estronsülfamat, estradiyolsülfamat, estriyolsülfamat veya asil zincirinde 7 adede kadar C atomu bulunan estronun, estradiyolün veya estriyolün N-asilsülfamati veya bu etki maddelerinden 2 veya daha fazlasinin bir kombinezonu kullanilmaktadir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19834931A DE19834931A1 (de) | 1998-07-28 | 1998-07-28 | Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200100234T2 true TR200100234T2 (tr) | 2001-06-21 |
Family
ID=7876248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/00234T TR200100234T2 (tr) | 1998-07-28 | 1999-05-13 | Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması. |
Country Status (28)
Country | Link |
---|---|
US (1) | US7053077B1 (tr) |
EP (1) | EP1100509B1 (tr) |
JP (1) | JP4891479B2 (tr) |
KR (1) | KR20010072082A (tr) |
CN (1) | CN1311683A (tr) |
AP (1) | AP2001002054A0 (tr) |
AR (1) | AR016502A1 (tr) |
AT (1) | ATE292468T1 (tr) |
AU (1) | AU766019B2 (tr) |
BG (1) | BG105171A (tr) |
BR (1) | BR9912466A (tr) |
CA (1) | CA2338558A1 (tr) |
CO (1) | CO5261567A1 (tr) |
DE (2) | DE19834931A1 (tr) |
EA (1) | EA003371B1 (tr) |
EE (1) | EE200100053A (tr) |
HK (1) | HK1040192A1 (tr) |
HU (1) | HUP0102913A3 (tr) |
IL (1) | IL141081A0 (tr) |
IS (1) | IS5819A (tr) |
MX (1) | MXPA01000548A (tr) |
NO (1) | NO20010468L (tr) |
NZ (1) | NZ509521A (tr) |
PL (1) | PL345588A1 (tr) |
SK (1) | SK1292001A3 (tr) |
TR (1) | TR200100234T2 (tr) |
WO (1) | WO2000006175A1 (tr) |
ZA (1) | ZA200100743B (tr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006027A1 (en) | 2001-07-13 | 2003-01-23 | Schering Aktiengesellschaft | Combination of drospirenone and an estrogen sulphamate for hrt |
US8026229B2 (en) | 2001-08-13 | 2011-09-27 | Sterix Limited | Antitumor-active 2-alkoxyestradiol sulfamates |
US8282612B1 (en) | 2008-03-07 | 2012-10-09 | Denise H. Miller | Methods and devices for intrauterine absorption |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP2647379A1 (en) * | 2012-04-05 | 2013-10-09 | PregLem S.A. | Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9078786B1 (en) | 2012-10-19 | 2015-07-14 | Denise H. Miller | Methods and devices for collecting body fluids |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5314694A (en) * | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
AU7075594A (en) * | 1993-06-29 | 1995-01-24 | Leiras Oy | Pack for use in, and method of hormonal replacement therapy |
DE4429397C2 (de) * | 1994-08-09 | 2003-11-20 | Jenapharm Gmbh | Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
DE4447715C2 (de) * | 1994-08-09 | 1998-02-05 | Jenapharm Gmbh | Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen |
DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
DE19610635A1 (de) * | 1996-03-11 | 1997-09-18 | Schering Ag | Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie |
IL123422A (en) * | 1997-03-05 | 2003-05-29 | Akzo Nobel Nv | USE OF 7alpha-METHYL-17alpha-ETHYNYL-ESTRANE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR THE TREATMENT OF ATHEROSCLEROSIS |
JP2002520346A (ja) * | 1998-07-17 | 2002-07-09 | ファルマシア・アンド・アップジョン・カンパニー | 避妊用皮下メドロキシプロゲステロンアセタート |
-
1998
- 1998-07-28 DE DE19834931A patent/DE19834931A1/de not_active Withdrawn
-
1999
- 1999-05-13 IL IL14108199A patent/IL141081A0/xx unknown
- 1999-05-13 BR BR9912466-1A patent/BR9912466A/pt not_active IP Right Cessation
- 1999-05-13 TR TR2001/00234T patent/TR200100234T2/tr unknown
- 1999-05-13 MX MXPA01000548A patent/MXPA01000548A/es unknown
- 1999-05-13 EA EA200100108A patent/EA003371B1/ru not_active IP Right Cessation
- 1999-05-13 PL PL99345588A patent/PL345588A1/xx unknown
- 1999-05-13 US US09/744,574 patent/US7053077B1/en not_active Expired - Fee Related
- 1999-05-13 DE DE59911879T patent/DE59911879D1/de not_active Expired - Lifetime
- 1999-05-13 JP JP2000562029A patent/JP4891479B2/ja not_active Expired - Fee Related
- 1999-05-13 KR KR1020017001165A patent/KR20010072082A/ko not_active Application Discontinuation
- 1999-05-13 AT AT99936276T patent/ATE292468T1/de not_active IP Right Cessation
- 1999-05-13 AP APAP/P/2001/002054A patent/AP2001002054A0/en unknown
- 1999-05-13 SK SK129-2001A patent/SK1292001A3/sk unknown
- 1999-05-13 CA CA002338558A patent/CA2338558A1/en not_active Abandoned
- 1999-05-13 EP EP99936276A patent/EP1100509B1/de not_active Expired - Lifetime
- 1999-05-13 CN CN99809213A patent/CN1311683A/zh active Pending
- 1999-05-13 EE EEP200100053A patent/EE200100053A/xx unknown
- 1999-05-13 NZ NZ509521A patent/NZ509521A/en unknown
- 1999-05-13 WO PCT/DE1999/001496 patent/WO2000006175A1/de active IP Right Grant
- 1999-05-13 AU AU51481/99A patent/AU766019B2/en not_active Ceased
- 1999-05-13 HU HU0102913A patent/HUP0102913A3/hu unknown
- 1999-07-26 CO CO99046902A patent/CO5261567A1/es not_active Application Discontinuation
- 1999-07-27 AR ARP990103678A patent/AR016502A1/es not_active Application Discontinuation
-
2001
- 2001-01-19 IS IS5819A patent/IS5819A/is unknown
- 2001-01-23 BG BG105171A patent/BG105171A/bg unknown
- 2001-01-25 ZA ZA200100743A patent/ZA200100743B/en unknown
- 2001-01-26 NO NO20010468A patent/NO20010468L/no not_active Application Discontinuation
-
2002
- 2002-03-01 HK HK02101596.4A patent/HK1040192A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EA003371B1 (ru) | 2003-04-24 |
EP1100509B1 (de) | 2005-04-06 |
EE200100053A (et) | 2002-06-17 |
HUP0102913A3 (en) | 2002-03-28 |
BG105171A (bg) | 2001-07-31 |
DE19834931A1 (de) | 2000-02-24 |
AU5148199A (en) | 2000-02-21 |
EA200100108A1 (ru) | 2001-12-24 |
CA2338558A1 (en) | 2000-02-10 |
ZA200100743B (en) | 2002-05-08 |
NO20010468L (no) | 2001-03-27 |
IS5819A (is) | 2001-01-19 |
CN1311683A (zh) | 2001-09-05 |
NZ509521A (en) | 2003-11-28 |
NO20010468D0 (no) | 2001-01-26 |
KR20010072082A (ko) | 2001-07-31 |
IL141081A0 (en) | 2002-02-10 |
SK1292001A3 (en) | 2001-07-10 |
PL345588A1 (en) | 2001-12-17 |
BR9912466A (pt) | 2001-04-17 |
CO5261567A1 (es) | 2003-03-31 |
JP4891479B2 (ja) | 2012-03-07 |
AP2001002054A0 (en) | 2001-03-31 |
AU766019B2 (en) | 2003-10-09 |
DE59911879D1 (de) | 2005-05-12 |
US7053077B1 (en) | 2006-05-30 |
JP2002521452A (ja) | 2002-07-16 |
MXPA01000548A (es) | 2002-04-08 |
EP1100509A1 (de) | 2001-05-23 |
HK1040192A1 (zh) | 2002-05-31 |
ATE292468T1 (de) | 2005-04-15 |
AR016502A1 (es) | 2001-07-04 |
HUP0102913A2 (hu) | 2002-01-28 |
WO2000006175A1 (de) | 2000-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200100234T2 (tr) | Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması. | |
AR028809A1 (es) | Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica | |
UA41401C2 (uk) | Фармацевтичний контрацептивний комбінований препарат | |
BR9709934A (pt) | Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga | |
KR960704553A (ko) | 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen) | |
RS20060348A (en) | Extended use combination comprising estrogens and progestins | |
TR200200406T2 (tr) | Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması | |
KR960706344A (ko) | 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne) | |
HRP20070188B1 (hr) | Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva | |
HUP0300335A2 (hu) | 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
UA37259C2 (uk) | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч | |
BR9710566A (pt) | M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio | |
WO2000042942A3 (en) | Buccal drug delivery system for use in male contraception | |
BR9915215A (pt) | Composição farmacêutica para liberação modificada de sensibilizador de insulina | |
PL356847A1 (en) | Hormonal composition based on a progesterone and an oestrogen and use thereof | |
ATE278406T1 (de) | Orales contrazeptivum | |
HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
PT1007052E (pt) | Combinacoes de progestinas de crescimento do endometrico e progestinas de atropia do endometrio com estrogenios, em contracepcao oral | |
HUP9901474A2 (hu) | Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához | |
TH55261B (th) | การใช้ไบโอเจนิคอีสโตรเจนซัลฟาเมทในการรักษาการทดแทนฮอร์โมน | |
JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive method | |
RU97110374A (ru) | Способ повышения приживляемости эмбрионов у овцематок-реципиентов введением прогестерона | |
RU2006126632A (ru) | Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль | |
HUP9903097A2 (hu) | Progesztogén-antiprogesztogén tartalmú gyógyszerkészítmény | |
BR0010968A (pt) | Preparação farmacêutica, embalagem farmacêutica, método de tratamento e uso de uma substância estrogenicamente ativa e substância progestogenicamente ativa na preparação de um medicamento |